Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT01076231 is a phase 1/2 interventional trial sponsored by Abramson Cancer Center at Penn Medicine. As of 21 Nov 2026, it is completed. It studies Cisplatin and Etoposide in Stage IIIA Non-small Cell Lung Cancer. The registry lists an enrollment of 34 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2010 and a primary completion date of 31 Dec 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01076231 |
| Status | Completed |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
| Enrollment | 34 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Stage IIIA Non-small Cell Lung Cancer |
| Drugs | Cisplatin and Etoposide |
| Start | 31 Jan 2010 |
| Primary completion | 31 Dec 2016 |
| Study completion | 24 May 2018 |
| Last update posted | 17 May 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jacob Shabason, MD
Abramson Cancer Center at Penn Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01076231
Each answer restates registry values shown on this page.
What is NCT01076231?
NCT01076231 is a phase 1/2 interventional trial sponsored by Abramson Cancer Center at Penn Medicine. It studies Cisplatin and Etoposide in Stage IIIA Non-small Cell Lung Cancer.
Who leads NCT01076231?
The registry names Jacob Shabason, MD (principal investigator, Abramson Cancer Center at Penn Medicine) as the overall official.
Where does NCT01076231 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01076231 study?
The registered drug and biological interventions are Cisplatin and Etoposide.
When did NCT01076231 end?
The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 24 May 2018. The sponsor last updated the record on 17 May 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.